Atlas Trials

Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection

Clinical trial NCT03820258 · TERMINATED

Trial details

NCT number
NCT03820258
Sponsor
Gilead Sciences
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatitis C Virus Infection
Start date
2019-01-28
Primary completion
2019-12-04
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.